Prime Minister Pham Minh Chinh asked the Health Minister to study two methods of treating COVID-19 patients proposed by Professor Nguyên Thanh Liêm, former director of the Central Children’s Hospital, in order to draw up a proper implementation plan.
>> Hanoi releases epidemiological map of COVID-19
>> Nguyên Thanh Liêm, first Vietnamese doctor to win the Nikkei Asia Prize
Treatment of a patient with COVID-19.
Photo: VNA / CVN
To help reduce the death rate of COVID-19 patients, Professor Nguyên Thanh Liêm proposed two new treatment methods that the world has successfully applied.
The first is the transfusion of convalescent plasma containing antibodies against the SARS-CoV-2 virus from recovered patients to patients at risk of severe disease.
This is not a new method. During the COVID-19 pandemic, many parts of the world applied this method and it helped reduce the death rate.
Due to the urgent pandemic situation, the designs and results of some previous studies are not very convincing. Notable, however, is Libster’s recent study, published in the prestigious New England Journal of Medicine, which shows that transfusion of plasma from recovered patients reduced the rate of respiratory failure and mortality compared to the control group that received saline. .
Deux points soulignés dans cette étude sont qu’ils ont administered du plasma convalescent aux patients très tôt, dans les 72 heures suivant l’apparition des symptômes, et qu’ils n’utilisent que du plasma avec des titres d’anticorps anti-viraux students.
Although the transfused subjects were people 65 years of age or older with underlying medical conditions, none of the patients had serious adverse events. The collection of plasma from donors is, in principle, the same as the collection of blood from blood donors. The method is easy to implement and inexpensive.
Professor Nguyên Thanh Liêm suggested to the Ministry of Health to order the Hospital for Hematology and Blood Transfusion in Ho Chi Minh City and the National Institute of Hematology and Blood Transfusion to soon establish a plasma bank containing antiviral antibodies for use in patients. high-risk.
The second is to inject mesenchymal stem cells into the umbilical cord in the early stages of patients with respiratory failure to prevent cytokine storm, the leading cause of death in patients with respiratory failure. This method has been used for respiratory failure of various causes. For COVID-19 patients, some studies show that stem cell transfusion can increase survival rate 2.5 times compared to the no-transfusion group.
Vietnam is currently mastering the technology to produce mesenchymal stem cells in large quantities, which, if studied and implemented, will be a promising method of reducing mortality.
VNA / CVN